A plain-English guide to how COPD progresses, based on the GOLD grades (airflow / FEV1). Understand each stage, what changes, and where treatment fits.
In short: COPD severity is graded 1–4 (GOLD) by how much airflow is limited, measured as FEV1 (the air you can force out in one second) as a percentage of predicted. Stopping smoking slows progression at every stage.
| Stage | What happens |
|---|---|
| GOLD 1 — Mild (FEV1 ≥ 80%) | Mild airflow limitation; often only a chronic cough, easily mistaken for normal ageing or a smoker’s cough. |
| GOLD 2 — Moderate (FEV1 50–79%) | Breathlessness on exertion; this is frequently when people first seek help and treatment begins. |
| GOLD 3 — Severe (FEV1 30–49%) | Greater breathlessness, reduced exercise capacity and more frequent flare-ups (exacerbations). |
| GOLD 4 — Very severe (FEV1 < 30%) | Severe airflow limitation; quality of life is markedly reduced and exacerbations can be life-threatening. |
Source: GOLD (Global Initiative for COPD) grades. Assessed by spirometry with a respiratory physician. Staging is a clinical assessment — only a qualified specialist can stage your condition.
Conventional, stage-appropriate treatment is the foundation for COPD. Stem-cell therapy is investigational for this condition — not an approved cure. For an honest, sourced look at the evidence, cost and open trials, see stem cell therapy for COPD & Lung Disease and what the success-rate data really shows.
COPD is typically described in 4 stages using the GOLD grades (airflow / FEV1). The stages chart how the condition progresses; the pace varies a lot between individuals.
The most advanced stage is “Very severe (FEV1 < 30%)” — Severe airflow limitation; quality of life is markedly reduced and exacerbations can be life-threatening.
Stem-cell therapy for COPD & Lung Disease is investigational, not an approved cure — see our honest, sourced overview of stem cell therapy for COPD & Lung Disease (evidence, cost and trials) before considering it.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite